Samir Patel of Askeladden Capital presented his thesis on Sotera Health (US: SHC) at Wide-Moat Investing Summit 2026.
Thesis summary:
Sotera Health provides outsourced sterilization for medical devices and pharma, which Samir calls a 50% margin toll road in healthcare. Sterilization is 1-2% of product cost but gates shipment: unsterilized product cannot be sold. FY2025 revenue was $1.2bn with $590m of adjusted EBITDA, a 51% margin, up from about $400m of EBITDA during COVID. Sterigenics (65% of revenue, 70% of EBITDA) and Nordion, the only Western supplier of cobalt-60 (16%/18%), carry the thesis; Nelson Labs testing (19%/12%) is secondary.
Samir describes a layered, self-reinforcing moat. Failure is catastrophic on a tiny line item, the airplane-bolt model. FDA files often specify method, facility and sometimes chamber, so re-validation can cost $1-3m and 18-36 months, reinforcing 3-5 year take-or-pay contracts. Sterigenics and STERIS hold roughly 80% of the outsourced market, a rational duopoly with 95-97% EtO utilization. Freight can cost 2-5x the sterilization, localizing competition, and Nordion’s cobalt-60 monopoly supplies even STERIS. Hence 3-4% pricing plus low-single-digit volume, and organic growth every year since 2005.
The discount stems from five years Samir calls the money pit. EtO emissions claims produced a $363m Illinois verdict in 2022 and a $408m Willowbrook settlement in 2023. Georgia courts have since granted summary judgment in some cases, leaving California, with about 120 claims, as the wildcard. Litigation has cost roughly $750m in all. Front-loaded NESHAP emissions-control capex and a once-in-20-years Nordion cobalt-60 project absorbed nearly all operating cash flow, while the private equity sponsor sold down and has now exited.
Samir sees an inflection. Consolidated capex stays elevated in 2026, near $200m (guidance $175-225m), then falls to about $110m in 2027, converting the margin into free cash flow. He sizes remaining litigation at roughly $225m, about 10% of debt and 5% of market cap, well below what has been paid. The regulatory spend may widen the moat; one large OEM has decided to move all its in-house volume to Sterigenics.
The shares recently traded near $16, about 11x EBITDA and 20x EV/NOPAT. Samir’s base-case fair value is roughly $22-23, 14-15x EBITDA or 25x NOPAT, with upside to about $26 if outsourcing and Nordion tailwinds hit; STERIS, a weaker business, historically traded near 15x EBITDA. From 2027 he expects a 5% FCF yield plus 5-7% growth, a low-teens compounder without re-rating, and a 20-25% IRR over two to three years if it re-rates. Key risks are California litigation, a shift to x-ray and pricing backlash.
Disclaimer
Wide-Moat Investing Summit 2026 was held from June 23-26, 2026. The content of this website is not an offer to sell or the solicitation of an offer to buy any security. The content is distributed for informational purposes only and should not be construed as investment advice or a recommendation to sell or buy any security or other investment, or undertake any investment strategy. There are no warranties, expressed or implied, as to the accuracy, completeness, or results obtained from any information set forth on this website. BeyondProxy’s officers, directors, employees, and/or contributing authors may have positions in and may, from time to time, make purchases or sales of the securities or other investments discussed or evaluated herein.
